Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
 Securities Case - EconoTimes)
NEW YORK, April 01, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that April 4, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Insys Therapeutics, Inc. (NASDAQ:INSY). Insys investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Insys was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain Insys employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, Insys’ financial statements were materially false and misleading at all relevant times. After a series of news articles revealed that the Company had allegedly engaged in illegal and improper off-label marketing of Subsys, the Company’s shares fell dramatically in price, thereby injuring investors.
What you can do
If you purchased shares of Insys stock, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Scott + Scott, Attorneys at Law, LLP Geoffrey M. Johnson, Esq. Joseph Halloran, Esq. (216) 229-6088, toll-free (866) 326-5057 [email protected] [email protected]
